Oslo, Norway, 20 September 2021

The Board of Directors of Nordic Nanovector ASA ("Nordic Nanovector" or the
"Company") has on 20 September 2021 decided to grant 350,000 Performance Share
Units ("PSUs") to the Company's new CEO and primary insider Mr. Erik Skullerud
in accordance with the authorisation granted at the Annual General Meeting held
on 28 April 2021 (the "AGM").

The terms and conditions of the PSUs, which are part of the Company's long-term
incentive plan for employees, are described on pages 25-27 in the Company's
annual report for 2020.

The PSUs are granted without consideration. The PSUs are non-transferable and
will vest three years after the date of grant subject to satisfaction of the
applicable vesting conditions. Each vested PSU will give the holder the right to
acquire one share in the Company at an exercise price corresponding to the par
value of the shares being NOK 0.20.

In accordance with the resolution at the AGM, the PSUs are secured by a
corresponding number of free-standing warrants. The sole purpose of the warrants
is to ensure delivery of shares in the Company upon exercise of the PSUs. The
warrants do not give the PSU holders (or the option holders) a right to
subscribe for any additional shares in the Company.

Mr. Skullerud will hold 350,000 PSUs and 0 shares after the transaction.

The allocation of PSUs is in accordance with the Board of Director's declaration
on salaries and other remuneration to the senior executive management, as
approved by the Company's AGM.

Primary insider notification pursuant to the Market Abuse Regulation article 19
are attached.

For further information, please contact:

Jan H. Egberts, Chairman

Cell: +31 6 1467 2518

Email: janegberts@aol.com

About Nordic Nanovector:

Nordic Nanovector is committed to develop and deliver innovative therapies to
patients to address major unmet medical needs and advance cancer care. The
Company aspires to become a leader in the development of targeted therapies for
haematological cancers. Nordic Nanovector's lead clinical-stage candidate is
Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to
advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with
substantial unmet medical need, representing a growing market forecast to be
worth nearly USD 26 billion by 2028. Nordic Nanovector retains global marketing
rights to Betalutin® and intends to actively participate in the
commercialisation of Betalutin® in the US and other major markets.

Further information can be found at www.nordicnanovector.com.

This information is subject to a duty of disclosure pursuant to the Market Abuse
Regulation article 19 and section 5-12 of the Securities Trading Act.